5^th International Conference on ^{Forensic Psychology & Criminology} September 07-08, 2020 Prague, Czech Republic

Peter A. Everts is the Chief Scientific Officer at EmCyte Corporation with a demonstrated history of working in the medical practice industry. He is Skilled in Medical Devices for biological therapies for use in Orthobiology-MSK, Spine, Chronic Wound Care, Cardiac Surgery, Reconstructive Surgery, Facial Aesthetics, Hair Regrowth, and other Regenerative Medicine applications.Peter A. Everts is an Strong research professional graduated from the University of Utrecht PhD program, and International ATMO, San Antonio, TX, USA.

Regenerative Medicine, Tissue Regeneration, Platelet Rich Plasma, bone marrow and adipose mesenchymal cells

He was born in 1947, education in mechanical engineering / textile technology at University of Stuttgart (Germany), 1974 Scientist Institute for Textile and Process Engineering (ITV Denkendorf) 1980 – 1998 Supervisor Biomedical Engineering Group, 1998 Director of ITV and Full Professor for Textile Technology / Biomedical Engineering, add. 2001 CEO ITV Product Service GmbH, 2006 Director Interuniversital Center for Biomedical Engineering Stuttgart-Tuebingen, Vicepresident and President German Soc. for Biomaterials Member of the Coucil Europ. Soc. Biomaterials Director and Member of the Board of several Center of Excellences Biomedical Engineering

bio materials for soft tissue replacement, Implants, artificial organs, tissue engineering, wound care

Denis Barritault graduated in Math and Physics, completed his Ph.D. in biochemistry in Paris University. Post doctoral in molecular immunology at Pasteur Institute and NYU as NIH Fogarty Fellow he joined INSERM unit in Paris as developmental biologist. He made the first description and patents of FGF extracted from retina in 1979 and 82 as skin and cornea healing agent, became full professor at Paris East University in 1985, founded and directed a CNRS Laboratory on cell and tissue regeneration until 2003. He is now President of OTR3, Emeritus Professor and author in over 200 publications and 29 patents.

tissue regeneration, molecular immunology

Professor Oleksandr Kukharchuk, M.D. (Doctor of Medical Science) has accomplished 15 yrs of progenitor cells therapy experience in Ukraine, and 7 yrs in India. Scientific Publications: 250, patents: 17. He developed regulatory documents for stem cells therapy to implement as official treatment in Ukraine. Has innovated technique, how to overcome biggest challenge in transplantation – “Rejection of foreign tissue”. Prof. Oleksandr Kukharchuk guided clinical trials for evaluation of progenitor cells transplantation efficacy in diabetes mellitus, chronic limb ischemia, myocardiodystrophy, liver cirrhosis, male infertility, aging and pancreonecrosis. He is author of the book “Stem cells: Experiment, Theory, Clinic. Embryonic, mesenchymal, neural, hematopoetic stem cells”. Approval Committee member of Health Ministry “Program of transplantation in Ukraine” 2006-2010, Director of Coordination Centre for Organs, Tissues and Cells Transplantation of the Ukraine Health Ministry, 2006-2010; Member of European Society of Transplantology from 2006; Member of European Society of Gene and Cell Therapy from 2012.

Biotechnology & Regenerative Medicine: stem cells 3D culture, stem cells exosomes, stem cells growth factors

Yaegaki K is a Doctor of Dental Science. He has completed his PhD in Medicine from Kureme University Medical Biochemistry and Post-doctoral studies from University of British Columbia. He was trained as Oral Maxillofacial Surgeon at School of Medicine Kurume University. His specialty was facial injuries and cancer. He is the Director and Head of Oral Health at Nippon Dental University, which is the oldest dental school in Asia, also a Dean of PhD program. He has published more than 100 papers and 20 books. He has been serving as an Editorial Board Member of repute.

stem cell research, regenerative medicine, tissue engineering etc

Takashi Tsuji has completed PhD from Niigata University and worked in JT Inc. He was Professor of Tokyo University of Science (2000-14) and is Team leader of RIKEN BDR (2014-Present). He is Visiting Professor of Kobe University, Tokyo Dental University, Kwansei University, Tokyo University of Science and Keio University. He has published more than 100 papers including review in journals and has been serving as an editorial board member of Scientific Reports. He is a Director of Organ Technologies Inc.

Regenerative Medicine, Organ Regeneration

Xiao-Dong Chen, M.D., Ph.D. is a Professor (tenured) in the Department of Comprehensive Dentistry and Chief of the Regenerative Medicine Program in the School of Dentistry at the University of Texas Health Science Center at San Antonio. Dr Chen’s group was the first to establish a culture system, using cell-free native ECM made by bone marrow stromal cells, for rapidly growing large numbers of high-quality non-hematopoietic stem cells (NHSCs) from various sources, including bone marrow and umbilical cord blood. To closely replicate the tissue specific microenvironment (niche) ex vivo, Dr. Chen and his team have extended their technology by developing a variety of 3D tissue-specific scaffolds for facilitating stem cell-based applications such as: 1) rejuvenating NHSCs from the elderly to establish a personal stem cell bank with large numbers of high-quality autologous cells for treating age-related diseases; 2) inducing NHSC differentiation into the salivary gland epithelial cell lineage for repairing damaged salivary gland; and 3) enhancing the efficacy of bone marrow-derived MSCs for treating community-acquired pneumonia. The cell culture technology has also been found to have other applications such as preserving pancreatic islet function, while reducing islet immunogenicity, for use in allograft transplantation to treat type I diabetes. Based on knowledge gleaned from studies of native tissue-specific ECMs (TS-ECMs), Dr. Chen’s group has been actively working on developing a series of defined tissue-specific ECMs to selectively control NHSC fate so that a homogenous population of committed cells (muscle, bone, cartilage, skin, etc) can be obtained for tissue regenerative purposes. To foster the translation of his laboratory discoveries, Dr. Chen co-founded a startup company in 2010 (StemBioSys, Inc.; www.stembiosys.com). During the last several years, the company has been developing technology for scaling up the production of stem cells for treating human diseases, and providing a unique platform for quickly developing broad collaborations with other research institutes and biotech companies for basic research and clinical applications.

Reconstitute tissue-specific stem cell niche in vitro to control stem cell fate for tissue regenerative purposes.

Dr. Purita is director of Institute of Regenerative and Molecular Orthopedics (www.stemcellorthopedic.com) in Boca Raton, Florida. Dr. Purita is a pioneer in the use of Stem Cells and Platelet Rich Plasma. He received a B.S. and MD degree from Georgetown Univ. Dr. Purita is board certified in Orthopedics by ABOS. He is a Fellow American College of Surgeons, Fellow American Academy Orthopedic Surgeons, and a Fellow American Academy of Pain Management. He has lectured and taught extensively throughout the world on the use of Stem Cells and Platelet Rich Plasma. He has helped countries develop Stem Cell policies.

Stem cell,regenerative medicine

lain Chapel is a Scientific Investigator at IRSN, Laboratory of Radiopathology and Experimental Therapies.For 25 years, he has been developing gene and cell therapy using non-human primates, immune-tolerant mice and rats to protect against the side effects of radiation. He collaborates with clinicians to develop strategies for treatment of patients after radiotherapy overexposures. He has participated in the first establishment of proof of concept of the therapeutic efficacy of Mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after total body irradiation. He is scientific investigator of Clinical phase II trial evaluating the efficacy of systemic MSC injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy (NCT02814864Hirsch Index 26.

Regenerative medicine, Cell therapy, scaffold, radiotherapy

Kara E. McCloskey, PhD, is a Founding and Associate Professor in the School of Engineering at the University of California, Merced. She received her BS and an MS in Chemical Engineering from The Ohio State University and her PhD through a joint program with Cleveland Clinic Foundation’s Biomedical Engineering Department and Ohio State University. She then completed her postdoctoral training in vascular stem cell and tissue engineering with Dr. Robert Nerem at the Georgia Institute of Technology. Her research is in the field of cardiovascular tissue engineering with a specific focus on deriving functional cell products from stem cells. Dr. Kara McCloskey has over 15 years of experience in the area of endothelial cell (EC) fate and cardiovascular tissue engineering.

Tissue Engineering,Cell therapy,Stem cells,Regenerative Medicine

Véronique Migonney received an Engineer Diploma in Materials Science (1981), a Master in Biomedical and Biomaterials Engineering (1982) and a PhD (1986) in Chemistry (Doctorate of State Es Physics specialty Chemistry - Supervisor M. Jozefowicz) from University Paris 13th. Véronique Migonney was director of the laboratory CSPBAT UMR 7244 CNRS UP13 from 2009 to 2016 and heads the team LBPS devoted to Biomaterials Sciences from 2002. She is a graduate of the Master of Chemistry and Health Engineering from 2004 to 2016. Véronique Migonney is Fellow of The International College of Fellows in Biomaterials Science and Engineering for its contribution to the functionalization of biomaterials surfaces. She was president of the French Society for Biomedical Engineering 2011-2013 and she is vice-president of the AGBM (Alliance for Biological and Medical Engineering). Her expertise is focused on biomaterials science: she is working for> 35 years in the field of bioactive polymers synthesis and grafting to functionalize biomaterials surfaces with the aim of controlling the response.

bio materials,bio medical engineering

Shaik O. Rahaman, PhD, is an Assistant Professor in the Department of Nutrition and Food science at the University of Maryland, USA. His laboratory is interested in elucidating the molecular signaling events underlying the pathogenesis of various inflammatory diseases, specifically, atherosclerosis and fibrosis. Dr. Rahaman earned his PhD in Molecular Biology at Jadavpur University, and a BS in Human Physiology (Honors), and an MS in Biophysics and Molecular Biology from University of Calcutta. From 2000-2014, Dr. Rahaman worked at Cleveland Clinic, Cleveland, USA, as a Postdoctoral Fellow, eventually as a Project Scientist studying signal transduction in Cell Biology and Oncology. He has received many awards and honors. Dr. Rahaman was honored with Elsa Albrecht Award by Cleveland Clinic, which is awarded for outstanding publication. During 2011-2014, Dr. Rahaman also served as an Assistant Professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, USA. In 2013, he was the recipient of the American Heart Association Scientist Development Grant. Dr. Rahaman is the author or co-author of 20 research papers on neurobiology, oncology, atherosclerosis, or fibrosis in high impact international peer-reviewed journals of repute including Cell Metabolism and Journal of Clinical Investigation. Dr. Rahaman has given numerous invited talks nationally and internationally, and is a reviewer/editorial board member in numerous scientific journals. Dr. Rahaman also served as a reviewer for National Institute of Health (USA).

Cell Biology and Oncology

Dr. Rajput is a consultant orthopaedics and stem cell transplant surgeon practicing for the last 33 years. He has been trained in orthopaedic surgery and stem cell transplantation at various national and international medical centres of repute. He has also received specialised training at Royal Liverpool University Hospital, Liverpool, U.K. In the last 5 years he has developed & established Stem Cell Transplantation as a new branch of medical science in India. He has also the credit of performing more than 2000 stem cell transplants till date. Dr. Rajput has shown the definitive results of Stem Cell Transplantation in various diseases, specially in the cases of Duchenne Muscular Dystrophy, Degenerative Arthritis of the Knee, Autism, CP, and Spinal Cord Injuries. He is also the pioneer in bringing other cell based therapies like T-Cell Immunotherapy and Dendritic Cell vaccine in India for resistant cases of Cancer where chemotherapy & Radiotherapy has failed.

Stem Cell Transplantation,Regenerative Medicine,Tissue Engieering.

Maria Cristina Tanzi had her Master Degree in Chemistry and Pharmaceutics, Milano University, in 1975 (with honors). From 1980 to 1989, she was Assistant Professor of Applied Chemistry at the Industrial Chemistry Department and from 1990 to 1998 at the Bioengineering Department, Politecnico di Milano,. From 1999 to 2007 she was Associate Professor of Chemical Bioengineering, from 2008 to 2012 she was Full Professor at the Bioengineering Department, and starting 2013 (until March 1st, 2014) at the Chemistry, Materials and Chemical Engineering Department of Politecnico di Milano.

Bio Materials,Tissue Engineering,Regenerative Medicine